Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2017 15:52 ET | Source: Gemphire Therapeutics

Gemphire to Present at the Oppenheimer Annual Healthcare Conference and the H.C. Wainwright NASH Investor Event

LIVONIA, Mich., March 16, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...
March 15, 2017 16:01 ET | Source: Gemphire Therapeutics

Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update

Announces Date for 2017 Annual Meeting of Stockholders Conference Call and Live Webcast, Today at 4:30 Eastern Time LIVONIA, Mich., March 15, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc....
March 13, 2017 06:30 ET | Source: Gemphire Therapeutics

Gemphire Therapeutics to Report Fiscal Year End 2016 Financial Results on Wednesday, March 15

LIVONIA, Mich., March 13, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
March 10, 2017 09:33 ET | Source: Gemphire Therapeutics

Gemphire Therapeutics Announces $12.5 Million Financing

LIVONIA, Mich., March 10, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
February 02, 2017 06:00 ET | Source: Gemphire Therapeutics

Gemphire Therapeutics to Participate in the Canaccord Genuity Rare Disease and Biopharma 1 on 1 Day and the RBC Capital Markets Global Healthcare Conference

LIVONIA, Mich., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the...
January 30, 2017 06:00 ET | Source: Gemphire Therapeutics

Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial

LIVONIA, Mich., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced interim data on the LDL-C primary endpoint from the ongoing open label COBALT-1...
January 18, 2017 17:00 ET | Source: Gemphire Therapeutics

Gemphire Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

LIVONIA, Mich., Jan. 18, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on January 16, 2017, the Compensation Committee of its Board of Directors, which is...
January 09, 2017 08:00 ET | Source: Gemphire Therapeutics

Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study

LIVONIA, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof...
January 05, 2017 08:39 ET | Source: Gemphire Therapeutics

Gemphire Therapeutics Provides Clinical Update

Enrollment in the ROYAL-1 Clinical Trial Investigating Gemcabene in Hypercholesterolemia Is Ahead of Plan and Expected to be Completed This Month – Data Expected in the Third Quarter of 2017 Interim...
November 29, 2016 16:15 ET | Source: Gemphire Therapeutics

Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LIVONIA, Mich., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP), today announced that on November 25, 2016, the Compensation Committee of its Board of Directors, which...